ArticleRheumatology (Oxford, England)2019
Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.
Article in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Systemic sclerosis and small bowel involvement: A systematic review of diagnostic approaches and current evidence.Seminars in arthritis and rheumatism · 2026Pooled it
- The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.Rheumatology (Oxford, England) · 2025Pooled it
- Proteome-wide serology reveals immune-defined subtypes of gastrointestinal disease in systemic sclerosis.bioRxiv : the preprint server for biology · 2026Article
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- Severe scleroderma colopathy at initial diagnosis of systemic sclerosis in a young man: a case report.Frontiers in medicine · 2026Article
- Clinical characteristics and treatment patterns of systemic sclerosis patients in China: a single-center retrospective study.Clinical and experimental medicine · 2025Observational
- Cellular Players in Gastrointestinal Involvement of Systemic Sclerosis: Insights into Pathogenesis.Cells · 2025Review
- Does body composition matter in patients with systemic sclerosis?Rheumatology (Oxford, England) · 2025Article
- A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.Current opinion in rheumatology · 2025Article
- Gastric dysrhythmias in patients with early systemic sclerosis: a cross-sectional study.Rheumatology advances in practice · 2024Article
- Associations Between Patterns of Esophageal Dysmotility and Extra-Intestinal Features in Patients With Systemic Sclerosis.Arthritis care & research · 2023Article
- Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis.Rheumatology international · 2023Article
- Acute Spontaneous Colonic Perforation in a Case of Newly Confirmed Scleroderma: Case Report.Interactive journal of medical research · 2023Article
- Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.Nature reviews. Rheumatology · 2023Review
- Slow Colonic Transit in Systemic Sclerosis: An Objective Assessment of Risk Factors and Clinical Phenotype.Arthritis care & research · 2023Article
- Systemic sclerosis.Lancet (London, England) · 2023Review
- Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies.Journal of clinical medicine · 2022Article
- Gastrointestinal symptom severity and progression in systemic sclerosis.Rheumatology (Oxford, England) · 2022Article
- Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.Arthritis research & therapy · 2022Article
- Exposure to silica and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
objectivesTo examine the incidence, predictors and outcomes associated with severe gastrointestinal (GI) disease in a large inception SSc cohort.
methodsSSc subjects with <2 years of disease duration were identified from two multicentre cohorts. Severe GI disease was defined as: malabsorption, hyperalimentation, pseudo-obstruction and/or ⩾10% weight loss in association with the use of antibiotics for bacterial overgrowth or oesophageal stricture. Kaplan-Meier, multivariate logistic regression and Cox proportional hazard analyses were performed to determine the cumulative incidence rate, independent clinical correlates and mortality rate associated with severe GI disease. A longitudinal mixed model was used to assess the impact of severe GI disease on the Short Form Health Survey.
resultsIn this inception SSc cohort, the probability of developing severe GI disease was estimated at 9.1% at 2 years and 16.0% at 4 years. In multivariate analysis, severe GI disease was associated with inflammatory myositis (odds ratio 4.68, 95% CI 1.65, 13.24), telangiectasias (odds ratio 2.45, 95% CI 1.19, 5.04) and modified Rodnan skin score (odds ratio 1.03, 95% CI 1.01, 1.07). Severe GI disease was associated with a >2-fold increase in the risk of death (hazard ratio 2.27, 95% CI 1.27, 4.09) and worse health-related quality of life [Short Form Health Survey physical (β = -2.37, P = 0.02) and mental (β = -2.86, P = 0.01) component summary scores].
conclusionSevere GI disease is common in early SSc and is associated with significant morbidity and increased mortality. More research is needed to understand, prevent and mitigate severe GI disease in SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.